Now Reading: Natco Pharma Vizag unit gets 4 USFDA observations
-
01
Natco Pharma Vizag unit gets 4 USFDA observations
Natco Pharma has received four observations from the United States Food and Drug Administration (USFDA) for its formulation development facility (FDF) in Visakhapatnam, Andhra Pradesh. The observations were issued after an inspection…
Natco Pharma has received four observations from the United States Food and Drug Administration (USFDA) for its formulation development facility (FDF) in Visakhapatnam, Andhra Pradesh. The observations were issued after an inspection of the plant.
The company said in a regulatory filing that the observations are procedural in nature and do not involve any data integrity issues. Natco Pharma added that it will respond to the USFDA within the stipulated timeline to address the observations and resolve them.
The Vizag FDF unit is one of Natco's key manufacturing sites for finished dosage forms. The stock of Natco Pharma closed marginally lower on the day of the announcement.
Indian Opinion Analysis
USFDA observations at an Indian pharma unit, even when procedural, can delay product approvals and affect export revenue. Natco's Vizag facility is central to its US business, which contributes a significant portion of its turnover. The company now has 15 working days to submit a corrective action plan. Failure to satisfy the regulator could lead to an import alert, though that outcome is rare for first-time procedural issues. Investors will watch for the next USFDA inspection outcome.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
